Agenus, Inc. (NASDAQ: AGEN) is a biotechnology company focused on the discovery and development of immuno-oncology therapies and vaccine adjuvants. Originally founded as Antigenics, Inc. in 1994, the company adopted the Agenus name in 2014 to reflect its expanded platform capabilities. Headquartered in Lexington, Massachusetts, Agenus combines proprietary antibody discovery technologies with novel checkpoint modulation approaches to address the challenges of cancer treatment and infectious diseases.
The company’s core business activities center on its QUILT™ platform, which integrates high-throughput antibody discovery, humanization, and engineering to generate fully human monoclonal antibodies. Agenus specializes in checkpoint modulators that target proteins such as CTLA-4, PD-1 and LAG-3 to enhance T-cell activity against tumors. In addition to its therapeutic pipeline, Agenus is a recognized provider of QS-21 Stimulon® adjuvant, a saponin-based vaccine enhancer licensed by global vaccine developers for use in oncology and prophylactic vaccine candidates.
Agenus maintains a global footprint through collaborations and partnerships with leading pharmaceutical and biotechnology companies in North America, Europe and Asia. Its agreements include research and development collaborations, license arrangements and co-development programs aimed at accelerating the translation of novel immunotherapies into clinical trials. The company also operates cGMP manufacturing facilities in the United States, supporting both its internal vaccine adjuvant supply and third-party partnerships.
Led by co-founder and Executive Chairman Garo H. Armen, Agenus is governed by an experienced management team with deep expertise in drug discovery, clinical development and commercial strategy. The leadership team includes veterans in oncology research, translational medicine and biomanufacturing, positioning the company to advance its pipeline through key clinical milestones and regulatory filings.
AI Generated. May Contain Errors.
